Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of$ 0.17. This compares to loss of $0.24 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 29.41%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of$ 0.32 per share when it actually produced a loss of $0.10, delivering a surprise of 68.75%.Over the last four quar ...